Skip to main content
SpringerLink
Log in

Osteoimmunology

Wnt antagonists: for better or worse?

  • News & Views
  • Published:

From Nature Reviews Rheumatology

View current issue Sign up to alerts

Molecules involved in developmental signaling pathways have emerged as therapeutic targets for various rheumatic diseases. New research sheds light on the consequences of interfering with these processes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Manipulating signaling pathways influences ankylosis in mice.

References

  1. Uderhardt, S. et al. Blockade of Dickkopf-1 induces fusion of sacroiliac joints. Ann. Rheum. Dis. doi: 10.1136/ard.2008.102046.

  2. Kansara, M. et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 119, 837–851 (2009).

    Article  CAS  Google Scholar 

  3. van der Heijde, D. et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 58, 1324–1331 (2008).

    Article  CAS  Google Scholar 

  4. Lories, R. J. U., Derese, I. & Luyten, F. P. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J. Clin. Invest. 115, 1571–1579 (2005).

    Article  CAS  Google Scholar 

  5. Diarra, D. et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13, 156–163 (2007).

    Article  CAS  Google Scholar 

  6. Park, M. C., Chung, S. J., Park, Y. B. & Lee, S. K. Suppression of bone morphogenetic proteins attenuates syndesmophytosis by down-regulating Smad pathway in aggrecan-induced spondylitis mice [abstract #484]. Arthritis Rheum. 58 (Suppl.), S346 (2008).

  7. Schett, G., Zwerina, J. & David, J. P. The role of Wnt proteins in arthritis. Nat. Clin. Pract. Rheumatol. 4, 473–480 (2008).

    Article  CAS  Google Scholar 

  8. Luyten, F. P., Tylzanowski, P. & Lories, R. J. Wnt signaling and osteoarthritis. Bone 44, 522–527 (2009).

    Article  CAS  Google Scholar 

  9. Canalis, E., Giustina, A. & Bilezikian, J. P. Mechanisms of anabolic therapies for osteoporosis. N. Engl J. Med. 357, 905–916 (2007).

    Article  CAS  Google Scholar 

  10. Luyten, F. P., Lories, R. J., Verschueren, P., De Vlam, K. & Westhovens, R. Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract. Res. Clin. Rheumatol. 20, 829–848 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Laboratory for Skeletal Development and Joint Disorders, Katholieke Universiteit Leuven, Belgium

    Rik J. Lories & Frank P. Luyten

Authors
  1. Rik J. Lories
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank P. Luyten
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank P. Luyten.

Ethics declarations

Competing interests

R. J. Lories and F. P. Luyten have acted as patent holders on behalf of Katholieke Universiteit Leuven for the use of noggin in the treatment of spondyloarthritis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lories, R., Luyten, F. Wnt antagonists: for better or worse?. Nat Rev Rheumatol 5, 420–421 (2009). https://doi.org/10.1038/nrrheum.2009.144

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2009.144

  • Springer Nature Limited

This article is cited by

Search

Navigation